Cambridge Investment Research Advisors
INMB icon

Cambridge Investment Research Advisors’s INmune Bio INMB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,375
Closed -$44K – 3891
2025
Q3 		$44K Sell
21,375
-11,200
-34% -$25.6K ﹤0.01% 3665
2025
Q2 		$75K Buy
32,575
+9,500
+41% +$69.7K ﹤0.01% 3500
2025
Q1 		$180K Buy
+23,075
New +$183K ﹤0.01% 3235

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

Cambridge Investment Research Advisors's INMB Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of INmune Bio (INMB) in Q4 2025, closing a stake of 21,375 shares — an estimated $44K sold.

Cambridge Investment Research Advisors first reported a position in INMB in Q1 2025 and held it in 3 quarters. The position peaked at $180K in Q1 2025. 74 funds tracked by Wall St. Rank hold INMB as of Q4 2025.

  • Cambridge Investment Research Advisors reported no remaining INmune Bio position as of Q4 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 21,375 INmune Bio shares in Q4 2025, an estimated $44K.
  • Cambridge Investment Research Advisors first reported a position in INmune Bio in Q1 2025 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's INmune Bio position peaked at $180K in Q1 2025.
  • 74 funds tracked by Wall St. Rank held INmune Bio as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.